Tema Oncology ETF Rating $42.33 -0.22 (-0.52%) As of 12:15 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrendsBuy This Stock Tema Oncology ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.CANC Aggregate RatingModerate Buy 2.72Holdings in CANC have an aggregate rating of Moderate Buy based on 398 analyst ratings issued in the past year covering 23 companies (69.8% of the portfolio).CANC Aggregate Price Target$42.30-0.07% DownsideHigh Prediction$42.30Average Prediction$42.30Low Prediction$42.30Holdings in CANC have an aggregate price target of $42.30 and a range of $42.30 to $42.30 covering 23 companies (69.8% of the portfolio).CANC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy1 Buy rating(s)Moderate Buy18 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Oncology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 23 CANC Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings6.26%RVMDRevolution Medicines$202.26+0.1%2.4215 of 5 stars2.91$161.79 -20.0%22Analyst Forecast5.51%COGTCogent Biosciences$37.50+0.5%2.3992 of 5 stars2.85$49.10 30.9%13Positive NewsEarnings ReportAnalyst Forecast5.49%LLYEli Lilly and Company$1,183.76-2.1%4.8606 of 5 stars2.83$1,292.18 9.2%30Trending NewsAnalyst DowngradeInsider TradeAnalyst Revision4.62%RHHBYRoche$54.71-1.4%4.024 of 5 stars2.36$60.00 9.7%11Analyst Revision3.54%BMYBristol Myers Squibb$63.97-1.1%4.2311 of 5 stars2.52$66.06 3.3%25Trending NewsAnalyst Revision3.50%ABBVAbbVie$250.05-0.3%4.9027 of 5 stars2.88$275.50 10.2%26Trending NewsAnalyst ForecastAnalyst Revision3.48%MRKMerck & Co., Inc.$134.46-0.8%4.373 of 5 stars2.68$135.50 0.8%22Trending NewsAnalyst ForecastInsider TradeAnalyst Revision3.13%IMNMImmunome$26.27-0.6%2.8571 of 5 stars2.85$34.64 31.8%13Trending NewsEarnings ReportAnalyst ForecastInsider TradeAnalyst Revision3.04%JNJJohnson & Johnson$260.81-0.5%4.8074 of 5 stars2.80$268.22 2.8%25Trending News2.84%CGONCG Oncology$73.90-1.1%2.5577 of 5 stars2.71$83.18 12.6%142.80%AMGNAmgen$412.66-1.2%3.8066 of 5 stars2.35$372.39 -9.8%31Analyst ForecastInsider Trade2.68%GMABGenmab A/S$31.84+1.6%4.4133 of 5 stars2.85$39.50 24.1%13Analyst Upgrade2.59%EXELExelixis$50.65+0.1%3.1116 of 5 stars2.32$49.79 -1.7%19Positive NewsAnalyst UpgradeInsider Trade2.52%IDYAIDEAYA Biosciences$36.13-1.5%2.6141 of 5 stars2.81$50.13 38.8%162.44%HALOHalozyme Therapeutics$98.35-2.3%3.874 of 5 stars2.62$91.20 -7.3%13Insider Trade2.25%ONCBeOne Medicines$346.06-2.8%4.4911 of 5 stars3.00$402.14 16.2%17Insider Trade2.10%ELVNEnliven Therapeutics$58.15+0.2%3.2851 of 5 stars2.71$72.67 25.0%71.96%LEGNLegend Biotech$20.24-0.1%3.0948 of 5 stars2.47$52.29 158.3%15News CoverageEarnings ReportAnalyst Forecast1.95%CELCCelcuity$92.19+6.5%3.6774 of 5 stars2.82$153.64 66.7%11Trending NewsEarnings ReportAnalyst ForecastGap Down1.93%BBIOBridgeBio Pharma$80.29-1.1%3.5518 of 5 stars2.83$100.79 25.5%23Trending NewsEarnings ReportAnalyst Forecast1.79%RLAYRelay Therapeutics$19.82-0.6%3.3876 of 5 stars2.86$25.83 30.3%141.71%ERASErasca$18.07+1.2%2.6612 of 5 stars2.64$21.91 21.3%11Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionGap Down1.65%ZLABZai Lab$25.86-0.7%2.5519 of 5 stars2.71$40.20 55.5%7News CoverageInsider TradeGap Down This page (NASDAQ:CANC) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersBSEM Is Officially on Nasdaq... The Next Chapter Begins!BioStem Technologies (NASDAQ: BSEM) debuted on Nasdaq August 7th, marking its move from OTC markets into a new...Huge Alerts | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredWall Street is staring at the wrong AI tradeAnthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...The Oxford Club | SponsoredAfter KDA, PRE, and OCEAN—this is the one17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Oncology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Oncology ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
